Publication | Open Access
Hypoxia-inducible factor-1α regulates β cell function in mouse and human islets
225
Citations
66
References
2010
Year
ImmunologyGlucose ToleranceCellular PhysiologyInsulin SignalingOxidative StressInflammationObesityMetabolic SyndromeCellular Regulatory MechanismCell SignalingHealth SciencesMolecular PhysiologyInsulin ManagementHypoxia (Medicine)Cell BiologyHuman IsletsSignal TransductionPhysiologyDiabetesGlucose IntoleranceMetabolic RegulationCell FunctionHypoxia-inducible Factor-1α RegulatesDiabetes MellitusMetabolismMedicine
Hypoxia-inducible factor-1alpha (HIF-1alpha) is a transcription factor that regulates cellular stress responses. While the levels of HIF-1alpha protein are tightly regulated, recent studies suggest that it can be active under normoxic conditions. We hypothesized that HIF-1alpha is required for normal beta cell function and reserve and that dysregulation may contribute to the pathogenesis of type 2 diabetes (T2D). Here we show that HIF-1alpha protein is present at low levels in mouse and human normoxic beta cells and islets. Decreased levels of HIF-1alpha impaired glucose-stimulated ATP generation and beta cell function. C57BL/6 mice with beta cell-specific Hif1a disruption (referred to herein as beta-Hif1a-null mice) exhibited glucose intolerance, beta cell dysfunction, and developed severe glucose intolerance on a high-fat diet. Increasing HIF-1alpha levels by inhibiting its degradation through iron chelation markedly improved insulin secretion and glucose tolerance in control mice fed a high-fat diet but not in beta-Hif1a-null mice. Increasing HIF-1alpha levels markedly increased expression of ARNT and other genes in human T2D islets and improved their function. Further analysis indicated that HIF-1alpha was bound to the Arnt promoter in a mouse beta cell line, suggesting direct regulation. Taken together, these findings suggest an important role for HIF-1alpha in beta cell reserve and regulation of ARNT expression and demonstrate that HIF-1alpha is a potential therapeutic target for the beta cell dysfunction of T2D.
| Year | Citations | |
|---|---|---|
Page 1
Page 1